Genomic Profiling

We provide a broad range of DNA and RNA sequencing services, generating high-quality somatic and germline molecular data along with therapeutic context to empower physicians to make data-driven decisions.


A different approach to next-generation sequencing

We provide worldwide access to a portfolio of comprehensive genomic profiling services for a variety of clinical sequencing needs.
Download our case studies to see how we support sequencing for research, clinical trials, and sponsored testing.

Tempus xT

Targeted Panel of 648 genes

Solid Tumor + Normal Test

Tempus xF

Targeted Panel of 105 genes

Liquid Biopsy Test

Tempus xE

19,000+ genes

Whole Exome Test

Download validation summary

Tempus xG (Powered by GeneDx)

88-gene and 52-gene germline panels

xG+ (extended hereditary cancers)
xG (common hereditary cancers)

Tumor/normal match DNA sequencing

Tumor/normal matched design provides accurate insight through true somatic identification with 27.7% fewer false positives than tumor-only analysis*.

Whole transcriptome RNA sequencing with validated fusion detection

RNA fusion analysis provides clinically-validated fusion detection and can provide more results than DNA-only sequencing.

Auto-conversion option to liquid biopsy

In the event of insufficient tumor tissue, you can choose to still receive a blood-based result, through a simple automatic conversion selection, providing genomic results without a delay.

Concurrent and longitudinal testing options

Simultaneous tissue and liquid biopsy testing can provide a comprehensive view of your patient and may offer insight into the evolution of cancer care throughout the course of disease.

Structured clinical data integration

In a retrospective study, at least one clinical option was reported for 96% of the cohort on the basis of Tempus NGS and matched clinical data.*

*Beaubier et al. Nature Biotechnology. 2019.

Clinical support tools & EMR integration

Tempus Hub

Tempus Hub

Our online Hub allows you secure, fast, reliable access to patient report status and results. View interactive and in-depth next-generation sequencing results in the context of a patient’s clinical history, filterable treatment applications and clinical trials, and PDFs of all Tempus reports.

You will also have access to our near real-time support tool that connects you with up-to-date treatment options and relevant insights derived from real-world clinical evidence across millions of de-identified patient records, our vast library of molecular profiling data, and our advanced analytics and machine-learning algorithms.

Download the Tempus mobile app.
The Tempus Order Summary

The Tempus Order Summary

After processing your entire order, we produce an order summary highlighting all key findings from the xT and xF tests along with additional tests like Tumor Origin, HRD, and DPYD, including actionable treatments, microsatellite instability (MSI) status, and tumor mutational burden (TMB) that can be quickly translated into cancer patient care.

Our reports are also embedded with Tempus Insights, patient-specific insights derived from real-world evidence to empower physicians with the necessary data to improve patient care.

Get in touch to learn more.


Tempus is the first genomic sequencing company to incorporate both Memorial Sloan Kettering Cancer Center’s OncoKB and NCCN Clinical Practice Guidelines (NCCN Guidelines®) into our smart clinical reports. MSK OncoKB & NCCN are two of the most robust oncology databases in the world. With the integration of these trusted sources, you can:

  • Optimize treatment plans for your patients
  • Stay updated with the latest indications and recommendations
Integration and Connectivity Solutions

Integration and Connectivity Solutions

With a dedicated team of integration experts, we offer a fully interoperable solution for clinical ordering and returning results back into an institution’s health IT systems. We can transform our report into discrete genomic data that can be loaded directly into your system(s) in industry standard HL7 format. In addition, we collaborate with partners to offer a fully interoperable structured result file format which can be parsed and loaded into an institution’s data ecosystem to power their precision medicine program. 

To ease the clinical ordering workflow, we support the automation of appropriate and secure data sharing to power your precision medicine program with Tempus clinical support and advanced analytics. If you have already ordered Tempus through paper or online methods, we can historically backfill prior results into your system(s). 

We understand the power of analytics and the positive impact it has on clinical support.

Contact us today.

The Tempus Sequencing Lab

Bringing data and technology into clinical care

We operate CAP-accredited, CLIA-certified robotic sequencing labs in Chicago, Atlanta, and Raleigh with automated bioinformatics and variant classification reporting. Sequencing is completed within 8-10 days on average of receiving patient samples.

Download our lab overview


The Benefits of Combining Molecular and Clinical Data for Patients

“Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials […] and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.”

Learn more about the xT 500 Publication in Nature Biotechnology

Combined DNA and RNA sequencing using Tempus|xT increased the high level therapy matching rate to 43.4% of patients.

Follow-Up Testing Covered Under Tempus Financial Assistance*

Any US-based patient who receives Tempus testing may apply for our Financial Assistance Program. If approved, the program covers all medically necessary xT (solid), xF (liquid) and xG (hereditary) testing within 18 months of approval.

* Tempus testing is always conducted based on the medical judgement of an ordering physician.

This is data-driven precision medicine.

This is the future of healthcare.